REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (âTevogenâ or âTevogen Bio Holdings Inc.â) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, g...